Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Morschhauser

Showing results (51-60 of 315) with videos related to

Pageof 32
Sort By:
Leukemia & Lymphoma|April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantSally Arai, Michelle Fanale, Sven DeVos, et al.
Reproductive Biomedicine Online|March 7, 2018
Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controlsChristine Decanter, Geoffroy Robin, Audrey Mailliez, et al.
Cancer|June 16, 2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)Franck Morschhauser, Nicolas Mounier, Catherine Sebban, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
British Journal of Haematology|February 4, 2015
Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphomaStéphanie Poulain, Eileen M Boyle, Sabine Tricot, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2022
<sup>18</sup>F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL PatientsKibrom B Girum, Louis Rebaud, Anne-Ségolène Cottereau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphomaLindsey Goff, Karin Summers, Sameena Iqbal, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|March 13, 2021
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapyDavid Beauvais, Oriane Karleskind, Severine Loridant, et al.
British Journal of Haematology|May 2, 2022
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphomaJesse G Dixon, Natalie Dimier, Tina Nielsen, et al.
Pageof 32

Showing results (51-60 of 315) with videos related to

Sort By:
Pageof 32
Leukemia & Lymphoma|April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantSally Arai, Michelle Fanale, Sven DeVos, et al.
Reproductive Biomedicine Online|March 7, 2018
Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controlsChristine Decanter, Geoffroy Robin, Audrey Mailliez, et al.
Cancer|June 16, 2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)Franck Morschhauser, Nicolas Mounier, Catherine Sebban, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
British Journal of Haematology|February 4, 2015
Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphomaStéphanie Poulain, Eileen M Boyle, Sabine Tricot, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2022
<sup>18</sup>F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL PatientsKibrom B Girum, Louis Rebaud, Anne-Ségolène Cottereau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphomaLindsey Goff, Karin Summers, Sameena Iqbal, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|March 13, 2021
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapyDavid Beauvais, Oriane Karleskind, Severine Loridant, et al.
British Journal of Haematology|May 2, 2022
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphomaJesse G Dixon, Natalie Dimier, Tina Nielsen, et al.
Pageof 32